Guska received two awards that highlight innovation in Uruguay: the SantanderX Award Uruguay 2025 and the PwC Uruguay Innovation Award 2025.
The SantanderX Award seeks to support and elevate the country’s best projects and startups in two categories: “Startup Award” and “University Award”.
Guska participated in the Startup category. It was initially selected among six semifinalists who applied for the award. The team presented a pitch to a jury composed of Santander Uruguay executives and was chosen, along with two other startups, to advance to the final round. At the LATU Innovation Campus, they delivered a four-minute pitch and were selected as the winners.
“This recognition motivates us to continue advancing in our mission to develop a new generation of RNA-based oncolytic virotherapies, grounded in synthetic biology and powered by artificial intelligence, with the aim of creating innovative treatments and reaching patients who urgently need better options,” the startup noted.
On the other hand, PwC Uruguay held the sixth edition of its Innovation Award, which seeks to promote the development and importance of innovation in society. The award is organized with the support of the National Research and Innovation Agency (ANII), the Inter-American Development Bank (IDB), and Búsqueda newspaper.
Guska won in the Startup Category, which received 39 applications. Meanwhile, Avedian won in the General Category.
“Congratulations to both teams on this well-deserved recognition. Their work is an example of how innovation addresses today’s challenges and drives transformation,” ANII stated.
